Adma Biologics (ADMA) Profit After Tax (2011 - 2026)

Adma Biologics (ADMA) has 13 years of Profit After Tax data on file, last reported at $49.4 million in Q4 2025.

• Quarterly Profit After Tax fell 55.87% year-over-year to $49.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $146.9 million (down 25.67% YoY) and the FY2025 annual result came in at $146.9 million, down 25.67% from the prior year.
• Profit After Tax improved to $49.4 million in Q4 2025, from $36.4 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $111.9 million in Q4 2024 to a low of -$25.0 million in Q1 2022.
• A 5-year average of $8.9 million and a median of -$6.6 million in 2023 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2024 — Profit After Tax surged 1299.96% — and 2025, when it sank 55.87%.
• Tracing ADMA's Profit After Tax over 5 years: stood at -$16.6 million in 2021, then climbed by 26.54% to -$12.2 million in 2022, then plunged by 44.26% to -$17.6 million in 2023, then jumped by 734.15% to $111.9 million in 2024, then slumped by 55.87% to $49.4 million in 2025.
• The last three Profit After Tax figures came in at $49.4 million (Q4 2025), $36.4 million (Q3 2025), and $34.2 million (Q2 2025), per Business Quant data.